DOP2017000294A - Unidad de dosificación orodispersable que contiene un componente estetrol - Google Patents

Unidad de dosificación orodispersable que contiene un componente estetrol

Info

Publication number
DOP2017000294A
DOP2017000294A DO2017000294A DO2017000294A DOP2017000294A DO P2017000294 A DOP2017000294 A DO P2017000294A DO 2017000294 A DO2017000294 A DO 2017000294A DO 2017000294 A DO2017000294 A DO 2017000294A DO P2017000294 A DOP2017000294 A DO P2017000294A
Authority
DO
Dominican Republic
Prior art keywords
dosage unit
estetrol
weight
solid dosage
component
Prior art date
Application number
DO2017000294A
Other languages
English (en)
Spanish (es)
Inventor
Jan Platteeuw Johannes
Johan Marijn Van Den Huevel Denny
Francine Isabelle Jaspart Severine
Original Assignee
Mithra Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mithra Pharmaceuticals S A filed Critical Mithra Pharmaceuticals S A
Publication of DOP2017000294A publication Critical patent/DOP2017000294A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DO2017000294A 2015-06-18 2017-12-11 Unidad de dosificación orodispersable que contiene un componente estetrol DOP2017000294A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15172767 2015-06-18

Publications (1)

Publication Number Publication Date
DOP2017000294A true DOP2017000294A (es) 2018-02-15

Family

ID=53496426

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000294A DOP2017000294A (es) 2015-06-18 2017-12-11 Unidad de dosificación orodispersable que contiene un componente estetrol

Country Status (42)

Country Link
US (4) US11147771B2 (enExample)
EP (2) EP3310333B1 (enExample)
JP (2) JP6866560B2 (enExample)
KR (2) KR102735893B1 (enExample)
CN (2) CN107787224A (enExample)
AU (4) AU2016280858B2 (enExample)
BR (1) BR112017027229B1 (enExample)
CA (1) CA2988495C (enExample)
CL (1) CL2017003209A1 (enExample)
CO (1) CO2017012670A2 (enExample)
CR (1) CR20180041A (enExample)
CU (1) CU24504B1 (enExample)
CY (2) CY1123006T1 (enExample)
DK (2) DK3701944T3 (enExample)
DO (1) DOP2017000294A (enExample)
EA (2) EA035687B1 (enExample)
EC (1) ECSP17085659A (enExample)
ES (2) ES2906228T3 (enExample)
GE (1) GEP20217243B (enExample)
HR (2) HRP20211968T1 (enExample)
HU (3) HUE057741T2 (enExample)
IL (1) IL256282B (enExample)
LT (3) LT3310333T (enExample)
MA (1) MA45972B1 (enExample)
MD (1) MD3310333T2 (enExample)
ME (1) ME03728B (enExample)
MX (1) MX384904B (enExample)
MY (1) MY186164A (enExample)
NO (1) NO2022020I1 (enExample)
NZ (2) NZ776452A (enExample)
PE (2) PE20231714A1 (enExample)
PH (1) PH12017502326A1 (enExample)
PL (2) PL3701944T3 (enExample)
PT (2) PT3701944T (enExample)
RS (2) RS62844B1 (enExample)
SI (2) SI3701944T1 (enExample)
SM (2) SMT202000251T1 (enExample)
SV (1) SV2017005596A (enExample)
TN (1) TN2017000497A1 (enExample)
UA (1) UA123099C2 (enExample)
WO (1) WO2016203006A1 (enExample)
ZA (1) ZA201708286B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161369T1 (hr) 2011-06-01 2016-12-02 Estetra S.P.R.L. Postupak za proizvodnju intermedijera estetrola
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP3310333B1 (en) 2015-06-18 2020-04-29 Estetra SPRL Orodispersible dosage unit containing an estetrol component
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
EP4221693A1 (en) 2020-09-29 2023-08-09 Millicent Pharma Limited Orodispersible formulations
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CL2021001762A1 (es) * 2021-07-01 2022-01-21 Univ Pontificia Catolica Chile Uso del estetrol como tratamiento para la endometriosis

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
CA1306950C (en) 1987-04-10 1992-09-01 Alec D. Keith Buccal administration of estrogens
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
GB2228412B (en) 1989-02-28 1993-04-14 Syntex Inc Nicardipine pharmaceutical composition for parenteral administration
JPH03237557A (ja) 1990-02-14 1991-10-23 Oki Electric Ind Co Ltd ニューラルネットワークシミュレータ及び計算機システム
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
AU2103495A (en) 1994-08-04 1996-03-04 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
KR100775154B1 (ko) 1997-12-19 2007-11-12 스미스클라인 비참 코포레이션 바이트-분산성 정제의 제조 방법
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
CA2390226A1 (en) 1999-12-02 2001-06-07 Akzo Nobel N.V. 14,15-beta-methylene substituted androgens
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
SI1611892T1 (sl) 2000-01-18 2010-01-29 Bayer Schering Pharma Ag Farmacevtski sestavki, ki obsegajo drospirenon
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
PT1390040E (pt) * 2001-05-18 2007-04-30 Pantarhei Bioscience Bv Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
ES2208518T3 (es) 2001-05-23 2004-06-16 Pantarhei Bioscience B.V. Medio y metodo anticonceptivo hormonal.
WO2002094277A1 (en) * 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Means and method for hormonal contraception
WO2002094278A1 (en) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
ES2296943T3 (es) 2001-05-23 2008-05-01 Pantarhei Bioscience B.V. Sistema de administracion de un medicamento estrogeno tetrahidroxilado destinado a la contracepcion hormonal.
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DE60216630T2 (de) 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
CA2476940C (en) 2002-02-21 2011-11-01 Herman Jan Tijmen Coelingh Bennink Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
ES2274252T3 (es) 2002-06-11 2007-05-16 Pantarhei Bioscience B.V. Metodo de tratamiento o prevencion de desordenes de medicion inmune y formulacion farmaceutica para su uso en ellos.
WO2003103685A1 (en) 2002-06-11 2003-12-18 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
US9034854B2 (en) 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
JP2005538150A (ja) 2002-08-28 2005-12-15 キャスパー,ロバート エストロゲン補充療法
WO2004037269A1 (en) 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
JP2006508945A (ja) 2002-11-05 2006-03-16 シエーリング アクチエンゲゼルシャフト 抗−アルドステロン性プロゲスチンを用いての心血管保護
EP1562976B1 (en) 2002-11-08 2010-05-26 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
EP1617859A1 (en) 2003-04-30 2006-01-25 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
DK1624878T3 (da) 2003-05-22 2007-01-08 Pantarhei Bioscience Bv Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte
AU2004275470B2 (en) 2003-09-29 2010-12-02 Novo Nordisk Health Care Ag Improved stability of progestogen formulations
PL1670440T3 (pl) 2003-09-29 2014-11-28 Novo Nordisk Healthcare Ag Preparaty HRT
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
PT1755562E (pt) 2004-05-28 2013-12-26 Richter Gedeon Nyrt Contraceptivo contendo ácido fólico
SI1773292T1 (sl) 2004-07-01 2009-10-31 Lek Pharmaceuticals D.D. Hitro razgradljiva oralno disperzibilna farmacevtska oblika
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
JP5305374B2 (ja) 2005-02-03 2013-10-02 タケダ ニコメド エイエス カルシウム含有組成物の製造のための速い湿式凝集方法
JP5004236B2 (ja) 2005-02-09 2012-08-22 キッセイ薬品工業株式会社 口腔内崩壊錠
IS7724A (is) 2005-03-02 2006-09-03 Actavis Group Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
JP5268635B2 (ja) 2005-05-26 2013-08-21 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 17β−HSD1及びSTSインヒビター
AU2006263638A1 (en) 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
ATE481973T1 (de) 2006-01-09 2010-10-15 Pantarhei Bioscience Bv Verfahren zur behandlung einer akuten gefässerkrankung
CA2640520C (en) 2006-03-02 2014-04-22 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
MX2008014941A (es) 2006-06-08 2008-12-10 Warner Chilcott Co Inc Metodos para administrar formas de dosificacion solida de etinil estradiol y profarmacos del mismo con biodisponibilidad mejorada.
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
US20070286819A1 (en) * 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
JP2009542588A (ja) 2006-07-06 2009-12-03 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 避妊及び先天的異常の危険性の予防のための医薬製剤
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
AR064014A1 (es) 2006-11-29 2009-03-04 Wyeth Corp Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina
AU2007338843B2 (en) 2006-12-20 2013-05-09 Teva Women's Health, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
CN101583363B (zh) 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
CN101631536A (zh) 2007-01-12 2010-01-20 惠氏公司 片中片组合物
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
ATE537833T1 (de) 2007-06-21 2012-01-15 Pantarhei Bioscience Bv Behandlung des mekoniumaspirationssyndroms mit östrogenen
PL2170346T3 (pl) 2007-07-19 2012-03-30 Pantarhei Bioscience Bv Leczenie lub profilaktyka zaburzeń związanych z nadciśnieniem w okresie ciąży lub opóźnienie wzrostu płodu
FR2920311B1 (fr) 2007-08-31 2010-06-18 Galenix Innovations Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation
JP5399749B2 (ja) 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
DK2262486T3 (da) 2008-08-01 2013-03-25 Krka Tovarna Zdravil D D Novo Mesto Quetiapin sammensætning
WO2010033832A2 (en) 2008-09-19 2010-03-25 Evestra, Inc. Estriol formulations
CN101780073B (zh) 2009-01-21 2013-07-03 重庆圣华曦药业股份有限公司 非布司他分散片药物及其制备方法
EP2210591B1 (en) 2009-01-26 2016-03-30 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
EP2410995A1 (en) 2009-03-26 2012-02-01 Royal College of Surgeons in Ireland Orodispersible tablets
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
KR20120044307A (ko) 2009-06-23 2012-05-07 바이엘 파마 악티엔게젤샤프트 긴급 피임용 제약 조성물
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
WO2011128338A1 (en) 2010-04-12 2011-10-20 Universite Claude Bernard Lyon I Method for preparing hybrid materials obtained by fast condensation of an organosilicon sol
JP5820465B2 (ja) 2010-04-15 2015-11-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Hrtのための極低用量固体経口投与形態
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
NZ611467A (en) 2010-12-02 2015-06-26 Aptalis Pharmatech Inc Rapidly dispersing granules, orally disintegrating tablets and methods
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
HRP20161369T1 (hr) 2011-06-01 2016-12-02 Estetra S.P.R.L. Postupak za proizvodnju intermedijera estetrola
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
CL2013003435A1 (es) 2011-06-01 2014-08-01 Estetra Sprl Proceso de preparacion de intermediarios de estetrol utilizando catalizadores de paladio y grupos protectores acilantes o sililantes; y uso de dicho proceso para preparar estetrol.
US10179107B2 (en) 2011-07-19 2019-01-15 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (DHEA)
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
PT2741824T (pt) 2011-08-11 2017-07-06 Estetra Sprl Utilização de estetrol como contracetivo de emergência
US9731018B2 (en) 2011-09-16 2017-08-15 Ferring B.V. Fast dissolving pharmaceutical composition
LT2764008T (lt) 2011-10-07 2016-11-10 Estetra S.P.R.L. Estetrolio gamybos būdas
EP2790688B1 (en) 2011-12-13 2019-11-20 Arstat, Inc. A multiphasic contraceptive regimen for an oral formulation of progestin and estrogen
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
US9238265B2 (en) 2012-09-27 2016-01-19 General Electric Company Backstrike protection during machining of cooling features
WO2014159377A1 (en) * 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
JP6126456B2 (ja) 2013-05-17 2017-05-10 東和薬品株式会社 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
US20140341326A1 (en) 2013-05-20 2014-11-20 Qualcomm Incorporated Channel estimation with discontinuous pilot signals
KR20160013098A (ko) 2013-05-21 2016-02-03 프리딕티브 테라퓨틱스, 엘엘씨 치료제 및 그 사용 방법
ES2624667T3 (es) 2013-09-18 2017-07-17 Crystal Pharma, S.A.U. Procedimiento para la preparación de estetrol
US12274276B2 (en) 2013-10-03 2025-04-15 Altria Client Services Llc Dissolvable-chewable tablet
US10772807B2 (en) * 2013-12-04 2020-09-15 Galderma Research & Development Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use of same in dermatology
SG11201604741UA (en) 2013-12-12 2016-07-28 Donesta Bioscience B V Orally disintegrating solid dosage unit containing an estetrol component
WO2016023009A1 (en) 2014-08-07 2016-02-11 Wake Forest University Health Sciences Compositions and methods for clearing a biological sample
EP3200802B1 (en) 2014-09-29 2023-07-12 The Regents of The University of California Compositions and methods for maintaining cognitive function
JP2018515552A (ja) 2015-05-18 2018-06-14 アジル・セラピューティクス・インコーポレイテッドAgile Therapeutics, Inc. 避妊用組成物ならびに有効性改善および副作用調節方法
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
EP3310333B1 (en) 2015-06-18 2020-04-29 Estetra SPRL Orodispersible dosage unit containing an estetrol component
SI3313408T1 (sl) 2015-06-23 2024-04-30 Laboratorios Leon Farma Sa Kontraceptiv na osnovi drospirenona za pacientko s prekomerno težo
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
MY205032A (en) 2016-10-28 2024-09-28 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
UA126746C2 (uk) 2018-02-07 2023-01-18 Естетра Спрл Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
US10929286B2 (en) 2018-06-29 2021-02-23 Seagate Technology Llc Arbitrated management of a shared non-volatile memory resource
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Also Published As

Publication number Publication date
AU2016280858B2 (en) 2021-06-24
CO2017012670A2 (es) 2018-03-28
IL256282B (en) 2022-01-01
CR20180041A (es) 2018-05-03
CU24504B1 (es) 2021-04-07
JP7140355B2 (ja) 2022-09-21
AU2022283615B2 (en) 2023-11-23
KR20230074847A (ko) 2023-05-31
BR112017027229A2 (pt) 2018-08-21
HUE049232T2 (hu) 2020-10-28
US20240238209A1 (en) 2024-07-18
CU20170161A7 (es) 2018-07-05
US20220096385A1 (en) 2022-03-31
BR112017027229B1 (pt) 2023-12-05
MY186164A (en) 2021-06-30
US12427114B2 (en) 2025-09-30
CA2988495A1 (en) 2016-12-22
LTC3701944I2 (enExample) 2023-12-27
SMT202000251T1 (it) 2020-07-08
ES2906228T3 (es) 2022-04-13
HUE057741T2 (hu) 2022-06-28
EP3701944A1 (en) 2020-09-02
IL256282A (en) 2018-02-28
MD3310333T2 (ro) 2020-06-30
US11793760B2 (en) 2023-10-24
SI3701944T1 (sl) 2022-04-29
NZ737945A (en) 2023-06-30
ZA201708286B (en) 2024-11-27
CA2988495C (en) 2022-02-08
NO2022020I1 (no) 2022-06-07
AU2016280858A1 (en) 2018-01-18
US20230293442A1 (en) 2023-09-21
PT3701944T (pt) 2022-01-11
PE20180522A1 (es) 2018-03-14
KR102662025B1 (ko) 2024-05-02
CY1124878T1 (el) 2022-11-25
PH12017502326B1 (en) 2018-06-25
PL3310333T3 (pl) 2020-07-13
KR20180019697A (ko) 2018-02-26
ES2800774T3 (es) 2021-01-04
AU2024201228A1 (en) 2024-03-14
SMT202200102T1 (it) 2022-05-12
JP2018521985A (ja) 2018-08-09
UA123099C2 (uk) 2021-02-17
EA202090984A1 (ru) 2021-02-26
NZ776452A (en) 2024-11-29
JP6866560B2 (ja) 2021-04-28
HK1254650A1 (en) 2019-07-26
EP3701944B1 (en) 2021-12-08
EA035687B1 (ru) 2020-07-27
EP3310333A1 (en) 2018-04-25
WO2016203006A1 (en) 2016-12-22
EP3310333B1 (en) 2020-04-29
PH12017502326A1 (en) 2018-06-25
ECSP17085659A (es) 2018-03-31
AU2021203265A1 (en) 2021-06-17
TN2017000497A1 (en) 2019-04-12
AU2022283615A1 (en) 2023-02-02
SV2017005596A (es) 2018-06-20
AU2024201228B2 (en) 2025-04-24
JP2021098710A (ja) 2021-07-01
RS62844B1 (sr) 2022-02-28
US11147771B2 (en) 2021-10-19
LTPA2022508I1 (enExample) 2022-06-27
MA45972B1 (fr) 2020-06-30
CY1123006T1 (el) 2021-10-29
US20180169022A1 (en) 2018-06-21
PT3310333T (pt) 2020-06-08
EA201890085A1 (ru) 2018-05-31
HUS2200027I1 (hu) 2022-07-28
CN116077455A (zh) 2023-05-09
RS60252B1 (sr) 2020-06-30
AU2021203265B2 (en) 2023-06-08
CN107787224A (zh) 2018-03-09
HRP20200850T1 (hr) 2020-10-02
LT3310333T (lt) 2020-06-25
MX384904B (es) 2025-03-14
ME03728B (me) 2021-01-20
DK3310333T3 (da) 2020-06-02
DK3701944T3 (da) 2022-03-14
CL2017003209A1 (es) 2018-04-13
PL3701944T3 (pl) 2022-04-04
SI3310333T1 (sl) 2020-08-31
LT3701944T (lt) 2022-04-11
KR102735893B1 (ko) 2024-11-29
MX2017016274A (es) 2018-06-19
US11964055B2 (en) 2024-04-23
HRP20211968T1 (hr) 2022-03-18
PE20231714A1 (es) 2023-10-23
GEP20217243B (en) 2021-04-26

Similar Documents

Publication Publication Date Title
DOP2017000294A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
ECSP17085669A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
CO2017000354A2 (es) Desmopresina estabilizada
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana